Sotrovimab for COVID-19

Sotrovimab is now available for Central Coast patients with COVID-19 who are at high-risk of developing severe disease. This includes immunocompromised patients, whether or not they have been vaccinated.

Sotrovimab works by binding to the spike protein on the outside of the COVID-19 virus. This is the same spike protein the body’s immune system is trained to recognise with the Pfizer COVID vaccine. By binding to the spike protein, sotrovimab can block the virus from attaching to and entering human cells - which stops the virus replicating in the body. In clinical trials sotrovimab was highly effective when administered to patients who had symptoms of COVID-19 for less than 5 days.

Central Coast Haematology encourage our patients to be tested immediately if they have any symptoms that may be due to COVID-19 to ensure they can be considered for sotrovimab therapy.

Sotrovimab does not replace vaccination which remains the most effective way of reducting the risk of acquiring COVID-19. Risk mitigation strategies (social distancing and mask wearing) also remain essential.

More information can be found: NSW Health information on sotrovimab